MitoQ recognised on international stage for its anti-ageing potential

MitoQ has been selected to join an exclusive group of compounds by the USA’s National Institute of Ageing’s (NIA) Interventions Testing Programme (ITP). The NIA-ITP is an internationally renowned and globally-recognised five-year anti-ageing testing programme funded by the US Government.

Since the NIA-ITP’s inception in 2004, there have been only 25 compounds selected by the programme, and MitoQ, the world’s first mitochondrial-targeted antioxidant formula is the first and only product from New Zealand to have been recognised. MitoQ will be acknowledged alongside compounds shown to extend age-span and health-span, such as rapamycin and aspirin, which were also selected for this programme and are now proven to positively impact longevity and health span.

Selection by the globally-recognised ITP programme validates a widening view within the research community that MitoQ confers anti-ageing benefits, as products must have shown significant potential to delay or decelerate the ageing process and improve general health if selected. The programme is renowned for its life-extending findings, and the compounds selected for the programme are tested over a five-year period to determine their impact on ageing.

MitoQ is a new advanced, next generation patented CoQ anti-oxidant which has been scientifically developed to reach the mitochondria 874x more effectively thanother forms of CoQ10. By targeting mitochondria, MitoQ supports optimal cell function and heart, liver and brain health, and has been proven to:

 

• Support: Heart, liver and brain health
• Assist: Energy, libido and healthy ageing
• Benefit those suffering with oxidative stress, mitochondrial dysfunction, multiple sclerosis, diabetes and chronic fatigue syndrome 

Dr Michael Murphy, Co-Founder of MitoQ and Group leader at Mitochondrial Dysfunction section of MRC Dunn Human Nutrition Unit, Cambridge UK) said,  "I'm delighted that MitoQ, the molecule Rob Smith and I developed in New Zealand over 15 years ago, is now being tested in the US National Institute of Ageing - Intervention Testing Program (NIA-ITP). While many compounds are claimed to affect ageing in mammals, to really assess this requires hugely expensive studies lasting several years. Only a handful of such studies have been done, mainly by the NIA-ITP. This program only selects a few of the most promising anti-ageing compounds for testing each year so their choosing MitoQ is very gratifying. During the program they will assesses the effects of MitoQ on a wide range of health markers. From this sort of study in the past the NIA-ITP has been able to confirm that some compounds (eg rapamycin) do decrease some of the negative effects of ageing and extend lifespan. Just as importantly, the NIA-ITP has also shown that other compounds that have been widely claimed to affect ageing (eg resveratrol) are actually ineffective. We will find out in a few years' time whether MitoQ does improve healthy ageing and slow the onset of ageing-associated diseases. The beauty of the NIA study is that the work is done to such a high standard and is entirely independent of anyone with an intellectual or commercial interest in MitoQ, that it will be hard to argue with the final findings.”